TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients

Targed biopharmaceuticals, UMC Utrecht spin-off and a portfolio company of UHSF, raised a Series A investment of €39 million to further develop Microlyse, a drug for acute Thrombotic Thrombocytopenic Purpura (aTTP) and Acute Ischemic Stroke (AIS), both thrombotic diseases. Results from pre-clinical studies are very promising. It is an invention of Dr. Coen Maas en Dr. Steven de Maat, both scientists from UMCU. In 2020, Utrecht Holdings entered into a license agreement with Targed for the development of Microlyse.

We look forward to the next steps!

Please read the press release.